Among these, the main families of oral medications include biguanides, where metformin is one of the first-line medications for the treatment of DM2; we also have sulfonylureas such as glibenclamide, glimepiride, etc. There are also thiazolinediones such as pioglitazone; α-glucosidase inhibitors such as acarbose and miglitol; DPP4 inhibitors such as sitagliptin, saxagliptin, etc.; and Sodium-glucose cotransporter-2 (SGLT2) inhibitors such as empagliflozin, dapagliflozin, etc. Finally, there is semaglutide, the most current oral drug of Glucagon-like peptide-1 (GLP-1) analogues [3,5,6]. This evidence concerns the gene GCG and myotonic dystrophy type 2.